Adverum Biotechnologies Inc (NASDAQ: ADVM ) announced a restructuring plan , including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD).
Adverum intends these restructuring measures to fully support its ADVM-022 development plan, providing it with ... Full story available on Benzinga.com